Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Crinetics Pharmaceuticals executive sells shares worth over $639k

Published 17/04/2024, 21:40
CRNX
-

In a recent transaction, Dana Pizzuti, the Chief Medical and Development Officer at Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), sold shares of the company's common stock, generating over $639,000. The sale took place on April 15, 2024, and was executed automatically under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks at a specific time.

The shares were sold at a volume-weighted average price of $44.47, with the range of sales prices between $43.98 and $44.75 per share. The total number of shares sold by Pizzuti was 14,375, which after the transaction, left her with 27,786 shares of Crinetics Pharmaceuticals still in her possession. This sale represents a significant transaction for Pizzuti, reflecting a substantial change in her investment in the company.

On the same day, Pizzuti also acquired 14,375 shares of common stock at a price of $16.89 per share, totaling approximately $242,793. This transaction was related to the exercise of stock options under the company’s equity incentive plan. The options exercised by Pizzuti are part of a grant that allows for the vesting of 25% of the shares on September 30, 2023, with the remainder vesting in thirty-six equal monthly installments, contingent upon her continued employment with Crinetics Pharmaceuticals.

Investors often monitor insider transactions as they can provide insights into the executive's view of the company's current valuation and future prospects. The transactions by Pizzuti were disclosed in a Form 4 filing with the Securities and Exchange Commission, which provides transparency into the trading activities of a company's insiders.

Crinetics Pharmaceuticals, based in San Diego, California, specializes in pharmaceutical preparations and continues to be a player in the life sciences industry. The company's stock performance and insider trading activities are closely watched by investors seeking to understand market trends and company health.

InvestingPro Insights

Crinetics Pharmaceuticals (NASDAQ:CRNX) has been the subject of investor attention following recent insider transactions. Here's a snapshot of the company's financial health and stock performance, based on real-time data from InvestingPro:

  • The company's market capitalization stands at $3.43 billion, reflecting its valuation in the current market.
  • Crinetics Pharmaceuticals is trading at a high Price / Book multiple of 6.36, suggesting that the market may be attributing a higher value to the company's net assets than the historical average.
  • The stock has experienced a robust one-year price total return of 155.67%, indicating strong performance over the past year.

Among the InvestingPro Tips, it's noted that Crinetics Pharmaceuticals holds more cash than debt on its balance sheet, which can be a sign of financial stability. Additionally, 5 analysts have revised their earnings upwards for the upcoming period, hinting at potential optimism about the company's future financial performance. However, it's important to note that analysts do not anticipate the company will be profitable this year.

For investors interested in a deeper analysis, there are 10 additional InvestingPro Tips available on the Crinetics Pharmaceuticals page at InvestingPro. These tips could provide further insights into the company's valuation, liquidity, and earnings outlook. To access these insights and more, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

With the next earnings date approaching on May 10, 2024, investors will be keen to see how the company's financials have evolved and whether the insider transactions align with the broader financial narrative of Crinetics Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.